| Pharmaceutical Information |
| Drug Name |
Estropipate |
| Drug ID |
BADD_D00836 |
| Description |
Not Available |
| Indications and Usage |
Not Available |
| Marketing Status |
Not Available |
| ATC Code |
Not Available |
| DrugBank ID |
Not Available
|
| KEGG ID |
D00948
|
| MeSH ID |
C009927
|
| PubChem ID |
5284555
|
| TTD Drug ID |
D03IUY
|
| NDC Product Code |
64918-0106; 12875-9998 |
| UNII |
SVI38UY019
|
| Synonyms |
estropipate | piperazine estrone sulfate | estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1) | Ogen | Harmogen | Genoral | Harmonet | Ortho-Est |
|
| Chemical Information |
| Molecular Formula |
C22H32N2O5S |
| CAS Registry Number |
7280-37-7 |
| SMILES |
CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Vulvovaginal inflammation | 21.14.02.014 | - | - | - |
|
|
|
